Nebenwirkungen · INOmax
INOmax 400 ppm mol/mol medicinal gas, compressed · Abschnitt 4.8 · PDF-Seite 8
HOS-108532 · Präparat HOS-093033
a: Identified from the clinical trial b: Identified from Post Marketing experience c: Identified from Post-Marketing experience, experienced by healthcare personnel following accidental exposure d: Post Marketing Safety Surveillance (PMSS) data, effects associated with acute withdrawal of the medicinal product, and /or delivery system failures. Rapid rebound reactions such as intensified pulmonary vasoconstriction and hypoxia after sudden withdrawal of inhaled nitric oxide therapy has been described, precipitating cardiovascular collapse.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-05-15T11:01:00Z · SHA-256 4c3ecbe485d3d0d3f3d8a8b72af806e039310534c247a674f80a0286630fc6f8 · Passage ce43562d365ab9113fbeebba65cece95e86e2bbc44c30093e144d754841dd7a9 · Zeichen 3463–4126 im Abschnitt